Secondary analyses evaluated ABASAGLAR® in patients previously treated with Lantus® insulin glargine STOCKHOLM, Sept. 15, 2015 / PRNewswire — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR® (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim’s biosimilar insulin glargine, demonstrated safety and efficacy outcomes similar to Lantus® insulin glargine in patients with […]
Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product
Web Desk No Comment Medical/Health Care
– New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and INGELHEIM, Germany, Dec. 20, 2013 / PRNewswire / Asianet-Pakistan – Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]
The post Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product appeared first on AsiaNet-Pakistan.